Search

Your search keyword '"Dreyfus, Brigitte"' showing total 8 results
Start Over Author "Dreyfus, Brigitte" Topic chronic lymphocytic leukemia
8 results on '"Dreyfus, Brigitte"'

1. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Author

Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), CHU Saint-Etienne, CHU UCL Namur, Groupe hospitalier de la région de Mulhouse Sud-Alsace (GHRMSA), CHU Grenoble, Centre Hospitalier Régional d'Orléans (CHRO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Nice (CHU Nice), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Catholique de Louvain = Catholic University of Louvain (UCL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université de Montpellier (UM), UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (MGD) Laboratoire de biologie clinique, UCL - (SLuc) Service d'hématologie, Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)

Subjects
0301 basic medicine, Male, Cancer Research, Neoplasm, Residual, MESH: Immunotherapy, Chronic lymphocytic leukemia, Gastroenterology, MESH: Clinical Trials, Phase III as Topic, 0302 clinical medicine, Bone Marrow, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, MESH: Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Aged, education.field_of_study, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, MESH: Follow-Up Studies, Prognosis, 3. Good health, Fludarabine, Survival Rate, Leukemia, MESH: Antineoplastic Combined Chemotherapy Protocols, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Vidarabine, MESH: Bone Marrow, Female, MESH: Rituximab, Immunotherapy, Rituximab, MESH: Clinical Trials, Phase II as Topic, Vidarabine, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Chemoimmunotherapy, Internal medicine, medicine, Humans, education, Survival rate, MESH: Neoplasm, Residual, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH: Cyclophosphamide, MESH: Retrospective Studies, medicine.disease, Leukemia, Lymphocytic, Chronic, B-Cell, MESH: Male, body regions, 030104 developmental biology, Clinical Trials, Phase III as Topic, Bone marrow, business, MESH: Female, Follow-Up Studies
Abstract

International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of the prognostic value of high-sensitivity (0.7 × 10-5) MRD assessment using flow cytometry, in blood (N = 401) and bone marrow (N = 339), after fludarabine, cyclophosphamide, and rituximab (FCR)-based chemoimmunotherapy in a homogeneous population with long follow-up (median 49.5 months). Addition of low-level positive MRD

Published
2020
Full Text
View/download PDF

2. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib

Author

Ghez, David, Calleja, Anne, Protin, Caroline, Baron, Marine, Ledoux, Marie-Pierre, Damaj, Gandhi, Dupont, Mathieu, Dreyfus, Brigitte, Ferrant, Emmanuelle, Herbaux, Charles, Laribi, Kamel, Le Calloch, Ronan, Malphettes, Marion, Paul, Franciane, Souchet, Laetitia, Truchan-Graczyk, Malgorzata, Delavigne, Karen, Dartigeas, Caroline, ysebaert, Loic, Group, French Innovative Leukemia Organization (filo) Cll, Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Le Mans (CH Le Mans), Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'hématologie biologique[Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Service d'Hématologie clinique [CHU Pitié-Salpêtrière], Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
0301 basic medicine, Male, medicine.medical_specialty, Time Factors, Chronic lymphocytic leukemia, [SDV]Life Sciences [q-bio], 030106 microbiology, Immunology, Neutropenia, Aspergillosis, Biochemistry, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Medical microbiology, Internal medicine, Medicine, Humans, In patient, Chronic, Leukemia, business.industry, B-Cell, Cell Biology, Hematology, medicine.disease, Lymphocytic, 3. Good health, Clinical trial, Pyrimidines, chemistry, 030220 oncology & carcinogenesis, Ibrutinib, Pyrazoles, Female, business
Abstract

International audience; Ibrutinib has revolutionized the management of chronic lymphocytic leukemia and is now being increasingly used. Although considered to be less immunosuppressive than conventional immunochemotherapy, the observation of a few cases of invasive fungal infections in patients treated with ibrutinib prompted us to conduct a retrospective survey. We identified 33 cases of invasive fungal infections in patients receiving ibrutinib alone or in combination. Invasive aspergillosis (IA) was overrepresented (27/33) and was associated with cerebral localizations in 40% of the cases. Remarkably, most cases of invasive fungal infections occurred with a median of 3 months after starting ibrutinib. In 18/33 cases, other conditions that could have contributed to decreased antifungal responses, such as corticosteroids, neutropenia, or combined immunochemotherapy, were present. These observations indicate that ibrutinib may be associated with early-onset invasive fungal infections, in particular IA with frequent cerebral involvement, and that patients on ibrutinib should be closely monitored in particular when other risk factors of fungal infections are present.

Published
2018
Full Text
View/download PDF

3. Characterisation of a new clinical presentation of chronic lymphocytic leukaemia: symptomatic bronchial involvement, a study from the FILO group.

Author

Nudel, Morgane, Baran‐Marszak, Fanny, Bossard, Jean‐Baptiste, Dubois, Romain, Dapvril, Héloïse, Dupuis, Jehan, Laribi, Kamel, Bay, Jacques‐Olivier, Tomowiak, Cécile, Dreyfus, Brigitte, Lepretre, Stéphane, Demarquette, Hélène, Wallyn, Frédéric, Wemeau, Lidwine, Wemeau, Mathieu, Poulain, Stéphanie, Morschhauser, Franck, Cymbalista, Florence, and Herbaux, Charles

Subjects
BRONCHIAL diseases, B cell receptors, CHRONIC lymphocytic leukemia
Abstract

Although a few cases of symptomatic bronchial involvement (SBi) associated with CLL (CLL SBi) have been reported, they were mostly from the pre-rituximab era (Chernoff I et al i , [2]; Palosaari & Colby, [8]; Desjardins I et al i , [3]; Maw I et al i , [7]). HRCT scans of the lungs of all CLL SBi patients showed a much higher frequency of anomalies of small airways and peripheral bronchi ( I P i = 0-001). Our findings document that SBi is a manifestation of CLL that should be considered along with CLL history when a patient presents with an unexplained obstructive respiratory condition. [Extracted from the article]

Published
2019
Full Text
View/download PDF

4. Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Author

Chaoui, Driss, Leprêtre, Stéphane, Liu, Kun Lun, Barry, Marly, Tempescul, Adrian, Dilhuydy, Marie-Sarah, Chaib, Abdelaziz, Slama, Borhane, Labourey, Jean Luc, Benbrahim, Omar, Dreyfus, Brigitte, Hacini, Maya, Mahé, Béatrice, Maynadié, Marc, Delmer, Alain, Benkanoun, Chahinez, Boissard, Frédéric, Gandon, Sophie, Veerabudun, Kalaivani, and Choquet, Sylvain

Subjects
CHRONIC lymphocytic leukemia, PROGRESSION-free survival
Published
2019
Full Text
View/download PDF

5. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.

Author

Chaoui, Driss, Choquet, Sylvain, Sanhes, Laurence, Mahé, Béatrice, Hacini, Maya, Fitoussi, Olivier, Arkam, Yazid, Orfeuvre, Hubert, Dilhuydy, Marie-Sarah, Barry, Marly, Jourdan, Eric, Dreyfus, Brigitte, Tempescul, Adrian, Leprêtre, Stéphane, Bardet, Aurélie, Leconte, Pierre, Maynadié, Marc, and Delmer, Alain

Subjects
DISEASE relapse, CHRONIC lymphocytic leukemia treatment, RITUXIMAB, ALKYLATING agents, ADVERSE health care events, HEMATOLOGY, NEUTROPENIA
Abstract

This prospective non-interventional study assessed the management of relapsed/refractory CLL after one or two treatments with rituximab, and retreatment with a rituximab-based regimen. An interim analysis was performed at the end of the induction period in 192 evaluable patients. Median age was 72 years [35–89], first relapse (55%), and second relapse (45%). Rituximab administered during first (68%), second (92%), or both treatment lines (20%). R-bendamustine administered in 56% of patients, R-purine analogs (21%), and R-alkylating agents (19%). The overall response rate (ORR) was 74.6%, in favor of R-purine analogs (90%), R-bendamustine (75%), and R-alkylating agents (69%). Lower ORR in Del 17p patients (43%) and third time rituximab (31%). Most frequent adverse events were hematological (23% patients) including neutropenia (11%) and infections (12%); grade 3/4 AEs (23% patients), mainly hematological (18%); death during induction treatment (7%). This first large study focusing on relapsed/refractory CLL patients retreated with rituximab-based regimens is still ongoing. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

6. IGHV gene mutational status and LPL/ ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide.

Author

Maloum, Karim, Settegrana, Catherine, Chapiro, Elise, Cazin, Bruno, Leprêtre, Stéphane, Delmer, Alain, Leporrier, Michel, Dreyfus, Brigitte, Tournilhac, Olivier, Mahe, Beatrice, Nguyen-Khac, Florence, Lesty, Claude, Davi, Frederic, and Merle-Béral, Hélène

Subjects
CHRONIC lymphocytic leukemia, CYTOGENETICS, CYCLOPHOSPHAMIDE, FLUDARABINE, FLOW cytometry, GENE expression
Abstract

Several prognostic factors can predict the rapid progression in chronic lymphocytic leukaemia (CLL), including IGHV mutational status, cytogenetic abnormalities and, more recently, LPL/ ADAM29 expression. In contrast, few studies have been devoted to the influence of these factors on clinical outcome in responding patients after therapy. We here propose to analyse the impact of IGHV gene status, LPL and ADAM29 gene expression on disease-free survival (DFS) and overall survival (OS) in 41 stage B or C CLL patients in remission after oral fludarabine plus cyclophosphamide. The median follow-up was of 64 (16–74) months. Sequencing of IGHV showed mutated (M) VH genes in 16 of 41 cases and unmutated (UM) in 25 cases. Analysis of LPL and ADAM29 expression in 35 of 41 cases showed overexpression of ADAM29 in 17 cases (14 M and three UM) and LPL in 18 cases (all UM). Patients expressing UM IGHV and LPL had shorter DFS and OS when compared to patients expressing M IGHV and/or ADAM29. Furthermore, blood minimal residual disease (MRD) evaluation using four-colour flow cytometry was performed in 33 out the 41 patients. We showed that patients who achieved phenotypic remission displayed longer DFS than those with MRD+. Our results support the use of LPL and ADAM29 gene expression associated to IGHV mutational status for predicting the clinical outcome of patients treated by oral fludarabine + cyclophosphamide and could be considered for treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

7. High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia.

Author

Cazin, Bruno, Divine, Marine, Leprêtre, Stéphane, Travade, Philippe, Tournilhac, Olivier, Delmer, Alain, Jaubert, Jérôme, Feugier, Pierre, Dreyfus, Brigitte, Mah, Béatrice, Grosbois, Bernard, Maloisel, Frédéric, Eghbali, Houchingue, Dumontet, Charles, Bénichou, Jacques, Guibon, Odile, Leleu, Xavier, Leporrier, Michel, and Maloum, Karim

Subjects
CHRONIC lymphocytic leukemia, LYMPHOPROLIFERATIVE disorders, DNA polymerases, POLYMERASE chain reaction, CHRONIC diseases, FLUDARABINE, ANTINEOPLASTIC agents
Abstract

A multicentre single-arm study testing the efficacy and toxicity of the oral combination of fludarabine and cyclophosphamide (FC) over 5 d in 75 patients with untreated B cell-chronic lymphocytic leukaemia. Oral FC demonstrated high efficacy with overall (OR) and complete response (CR) rates of 80% and 53%, respectively. Out of the 30 CR patients studied for Minimal Residual Disease (MRD) using 4-colour flow-cytometry and the 22 using Clonospecific polymerase chain reaction, 22 (66%) and 16 (68%), respectively, were MRD negative. Median survival and median treatment-free interval had not been reached at 7 years of follow-up. Median progression-free survival (PFS) was 5 years. Toxicity was acceptable, with 52% and 16% of National Cancer Institute grade 3/4 neutropenia and infections, respectively. Gastrointestinal toxicity was mild. Oral FC demonstrated a high efficacy and an acceptable safety profile and may be considered as the standard first line treatment in chronic lymphocytic leukaemia. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

8. Chlorambucil in Indolent Chronic Lymphocytic Leukemia.

Author

Dighiero, Guillaume, Maloum, Karim, Desablens, Bernard, Cazin, Bruno, Lepeu, Gérard, Navarro, Maurice, Leblay, Robert, Leporrier, Michel, Jaubert, Jérome, Dreyfus, Brigitte, Binet, Jacques-Louis, Travade, Philippe, Turpin, François-Louis, Tertian, Gérard, and Bichoffe, Agnès

Subjects
*CHRONIC lymphocytic leukemia, *DRUG therapy
Abstract

Background: To determine whether chlorambucil treatment benefits patients with indolent chronic lymphocytic leukemia (CLL), we conducted two randomized trials in 1535 patients with previously untreated stage A CLL. Methods: In the first trial, 609 patients were randomly assigned to receive either daily chlorambucil or no treatment; in the second trial, 926 patients were randomly assigned to receive either intermittent chlorambucil plus prednisone or no treatment. Median follow-up for the first and second trials exceeded 11 and 6 years, respectively. The end points were overall survival, response to treatment, and disease progression. Results: Treatment of indolent CLL did not increase survival in either trial. In the treated group, as compared with the untreated group, the relative risk of death was 1.14 (95 percent confidence interval, 0.92 to 1.41; P=0.23) in the first trial and 0.96 (95 percent confidence interval, 0.75 to 1.23; P=0.74) in the second trial, with 76 percent and 69 percent of patients, respectively, having a response to therapy. Although chlorambucil slowed disease progression, there was no effect on overall survival. In the untreated group in the first trial, 49 percent of patients did not have progression to more advanced disease and did not need therapy after follow-up of more than 11 years; however, 27 percent of patients with stage A CLL died of causes related to the disease. Conclusions: Chlorambucil does not prolong survival in patients with stage A CLL. Since deferring therapy until the disease progresses to stage B or C does not compromise survival, treatment of indolent CLL is unnecessary. (N Engl J Med 1998;338:1506-14.) [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results